ABCL · AbCellera Biologics Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on ABCL. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About ABCL · AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Live Quote
HOLD (score +3) · 12-1 mom 39.7% · RSI 55.9 · above_both · -12.8% from high
Targets blend Wall Street consensus (7 analysts: low $7.00 / mean $10.43 / high $13.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
recent scout:failed 0.4h ago < cooldown 1h, no material change